Series of hepatitis B treatments enter Seoul National University Hospital, warning fierce competition

Published: 2018-02-06 16:30:00
Updated: 2018-02-06 15:58:49

As Ildong Pharmaceutical’s ‘Besivo’ entered Seoul National University Hospital January after Gilead Sciences’ ‘Vemlidy’ last December, it has notified even fiercer competition in the chronic type B hepatitis market. The two products were also landed together on Severance Hospital last November.



- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.